The SUVmax of 18F-FDG PET correlates with histological grade in endometrial cancer

International Journal of Gynecological Cancer

Volumn 20, Issue 1, 2010, Pages 110-115

  Nakamura, Keiichiro ^a   Kodama, Junichi ^a   Okumura, Yoshihiro ^a   Hongo, Atsushi ^a   Kanazawa, Susumu ^a   Hiramatsu, Yuji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

18F FDG PET; Endometrial cancer; FIGO grade; GLUT 1; Maximum tumor size; SUVmax

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FUROSEMIDE; GLUCOSE TRANSPORTER 1; DIAGNOSTIC AGENT; SLC2A1 PROTEIN, HUMAN; TUMOR MARKER;

ABDOMINAL HYSTERECTOMY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAXIMUM STANDARDIZED UPTAKE VALUE; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; SURGICAL TECHNIQUE; TUMOR LOCALIZATION; TUMOR VOLUME; AGED; CANCER STAGING; CLINICAL TRIAL; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SCINTISCANNING; STANDARD;

AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; REFERENCE STANDARDS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 74249114553     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181c3a288     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Annual Report of Oncology Committee of Japan Society of Obstetrics and Gynecology, Tokyo, Japan 2009.
3. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10-17.
4. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683-693.
5. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6: 3837-3844.
6. Buck A, Schirrmeister H, Kühn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29:1317-1323.
7. Kurokawa T, Yoshida Y, Kawahara K, et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer. 2004;109:926-932.
8. Chung JK, Lee YJ, Kim SK, et al. Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and nonYsmall-cell lung cancer. Nucl Med Commun. 2004;25: 11-17.
9. Mamede M, Higashi T, Kitaichi M, et al. [18F]FDG uptake and PCNA, Glut-1, and hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 2005;7: 369-379.
10. Kunkel M, Reichert TE, Benz P, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003;97:1015-1024.
11. van Baardwijk A, Dooms C, van Suylen RJ, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1 alpha and GLUT-1 in nonYsmall cell lung cancer. Eur J Cancer. 2007;43:1392-1398.
12. Paulino AC, Johnstone PA. FDG-PET in radiotherapy treatment planning: Pandora's box? Int J Radiat Oncol Biol Phys. 2004; 59:4-5.
13. Fukui MB, Blodgett TM, Snyderman CH, et al. Combined PET-CT in the head and neck: part 2. Diagnostic uses and pitfalls of oncologic imaging. Radiographics. 2005;25: 913-930.
14. Hickeson M, Yun M, Matthies A, et al. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging. 2002;29: 1639-1647.
15. Lerman H, Metser U, Grisaru D, et al. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med. 2004;45:266-271.
16. Airley R, Loncaster J, Davidson S, et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res. 2001;7:928-934.
17. Ito T, Noguchi Y, Satoh S, et al. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol. 1998;11:437-443.
18. Noguchi Y, Marat D, Saito A, et al. Expression of facilitative glucose transporters in gastric tumors. Hepatogastroenterology. 1999;46:2683-2689.
19. Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998;83:34-40.
20. Ozbudak IH, Karaveli S, Simsek T, et al. Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas. Gynecol Oncol. 2008;108:603-608.